glp-1 agonists and pancreatitis The pancreatic and extrapancreatic effect
Description
PMID: 18541709
No long-term lock-in required, except for aligned medication subscriptions
In April 2005 the US Food and Drugs Administration (FDA) approved a synthetic version, called exenatide, to treat type 2 diabetic patients unable to sufficiently control their blood sugar levels with other diabetic medications like metformin, and sulfonylureas
Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events
Circadian Rhythms of Plasma Renin Activity and Aldosterone: Changes Related to Age, Sex, Recumbency and Sodium Restriction
Possible mechanisms underlying the effects of glucagon-like peptide-1 receptor agonist on cocaine use disorder
